ArticleBritish dental journal2018
MRONJ risk of adjuvant bisphosphonates in early stage breast cancer.
Article in British dental journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Incidence and associated factors of medication-related osteonecrosis of the jaw in breast cancer patients with bone metastases: a nationwide registry study in Finland.Clinical oral investigations · 2026Article
- A qualitative analysis of dental challenges for oncology patients receiving bone-modifying agents.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Medication-related osteonecrosis of the jaw in breast cancer patients: a longitudinal observational Swedish study of oral health and antiresorptive use.BMC oral health · 2026Observational
- Medication-related osteonecrosis of the jaw in multiple myeloma patients: a case series.British dental journal · 2026Article
- Important learning points for setting up a dental-oncology service in Ireland.Irish journal of medical science · 2026Article
- Photobiomodulation in Medication-Related Osteonecrosis of the Jaw: Outcomes in Stage I and Its Adjunctive Role in Advanced Cases.Biomedicines · 2025Article
- A retrospective cohort study of the oral healthcare needs of cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 4: miscellaneous cancers.British dental journal · 2022Article
- The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 2: breast cancer.British dental journal · 2022Article
- Photodynamic Therapy as an adjunct in the Treatment of Medication-Related Osteonecrosis of the Jaw: A Case Report.Journal of lasers in medical sciences · 2021Article
- The prosthodontic management of medication-related osteonecrosis of the jaw: a case report.British dental journal · 2021Article
- The Novel Antioxidant Compound JSH-23 Prevents Osteolysis by Scavenging ROS During Both Osteoclastogenesis and Osteoblastogenesis.Frontiers in pharmacology · 2021Article
- Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Review
- Deciphering novel chemotherapy and its impact on dentistry.British dental journal · 2020Article
- Article
- No studies.British dental journal · 2018Article
Corrections and comments
- Commented on byNo studies.2018
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) has most commonly been associated with bisphosphonates. The routine uses of these drugs are now well established predominantly in metastatic cancer with bone involvement, multiple myeloma, hypercalcaemia, osteoporosis and Paget's disease. Recently, however, the use of bisphosphonates in early breast cancer has shown a reduction in breast cancer recurrence and breast cancer deaths. This new indication for their use approximates to a further 20,000 women per year in the UK being prescribed bisphosphonates. In this article, we consider the dental impact of this new use of bisphosphonates, report on the rates of MRONJ seen in early breast cancer bisphosphonate trials and discuss strategies aimed at minimising the risk of bisphosphonate-exposed patients developing MRONJ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.